Log in to search using one of your social media accounts:

 

Respicardia launches Remed ē system, taps Sommerness as CEO

Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to engage the diaphragm to restore natural breathing during sleep and improve patient quality of life and satisfaction. “Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality. Being able to treat CSA offers a new hope to improve the quality of life for my patients,” Dr. William Abraham of the Ohio State University Wexner Medical Center said in prepared remarks. The procedure treating the first patient was performed by Dr. Ralph Augostini at Columbus’ Ohio State University Wexner Medical Center, the Minnetonka, Minn.-based company said. “The Remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient’s quality of life. I am proud to be a part of the system’s first U.S. commercial case that has the potential to become the standard of care for these patients,” Dr. Augostini said in a prepared statement. Prior to joining Respicardia, Sommerness served as a partner at McKinsey and Comp...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Neuromodulation/Neurostimulation Respiratory Respicardia Source Type: news

Related Links:

Follow me on Twitter @RobShmerling Ever wonder what other people are wondering about? I know I do. So, here are the top 10 health searches in Google for 2017. And just so you don’t have to look each one up, I’ve provided a brief answer. You’re welcome. 1.  What causes hiccups? I was surprised this one made it to the top 10 list of health searches. Maybe this search is common because hiccups are as mysterious as they are universal. I’ve written about hiccups before, but let’s just say the cause in any individual person is rarely known or knowable. Then again, the reason hiccups stop is als...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Source Type: blogs
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
Persistent fatigue is a common problem ( ∼20-45% of U.S. population), with higher prevalence and severity in people with medical conditions such as cancer, depression, fibromyalgia, heart failure, sleep apnea and multiple sclerosis. There are few FDA-approved treatments for fatigue and great disagreement on how to measure fatigue, with o ver 250 instruments used in research. Many instruments define fatigue as “a lack of energy”, thus viewing energy and fatigue states as opposites on a single bipolar continuum.
Source: Medical Hypotheses - Category: Biomedical Science Authors: Source Type: research
AbstractRenal afferent and efferent sympathetic nerves are involved in the regulation of blood pressure and have a pathophysiological role in hypertension. Additionally, several conditions that frequently coexist with hypertension, such as heart failure, obstructive sleep apnea, atrial fibrillation, renal dysfunction, and metabolic syndrome, demonstrate enhanced sympathetic activity. Renal denervation (RDN) is an approach to reduce renal and whole body sympathetic activation. Experimental models indicate that RDN has the potential to lower blood pressure and prevent cardio-renal remodeling in chronic diseases associated wi...
Source: Clinical Autonomic Research - Category: Research Source Type: research
The objective of this study was to investigate whether uvulopalatopharyngoplasty (UPPP) reduced the risk of cardiovascular complications for patients with OSA.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Original Article Source Type: research
Authors: Terziyski K, Draganova A Abstract Characterized by periodic crescendo-decrescendo pattern of breathing alternating with central apneas, Central sleep apnea (CSA) with Cheyne-Stokes Breathing represents a highly prevalent, yet underdiagnosed comorbidity in chronic heart failure (CHF). A diverse body of evidence demonstrates increased morbidity and mortality in the presence of CSB. CSB has been described in both CHF patients with preserved and reduced ejection fraction, regardless of drug treatment. Risk factors for CSB are older age, male gender, high BMI, atrial fibrillation and hypocapnia.The pathophysiol...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
ConclusionsThis study adds to growing evidence that cardiovascular risk from TRT may be less than once feared. The increased risk of sleep apnea in men using TRT is noteworthy. The study strengths include the large number of healthy and young men exposed to TRT. Limitations include the retrospective study design inability to account for granular details of TRT use such as dosage, specific forms of TRT and serum testosterone levels pre‐ and post‐TRT.This article is protected by copyright. All rights reserved.
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
AbstractBackgroundReduced sleep quality is associated with impaired quality of life and increased mortality in patients with heart failure. The aim of this study was to observe changes in sleep fragmentation and sleep quality in patients with heart disease and preserved left ventricular ejection fraction (pEF) treated with adaptive servo-ventilation (ASV) therapy for treatment of emergent central sleep apnea (TECSA) or central sleep apnea (CSA).Methods114 patients with structural heart disease and pEF introduced to ASV therapy between 2010 and 2015 were retrospectively analyzed. Patients were stratified into two groups; TE...
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
AbstractPurposeApneaLink is a portable device for the screening of sleep apnea, a prevalent and underdiagnosed comorbidity in heart failure patients. A prospective cross-sectional study in patients with chronic heart failure was carried out to assess the sensitivity and specificity of apnea-hypopnea index (AHI) measurements using ApneaLink against the standard polysomnography test.MethodsAdult patients with a prior hospitalization in an acute heart failure hospital unit were recruited for the study. All participants were tested for sleep apnea using ApneaLink and polysomnography simultaneously during an overnight stay at a...
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
M, Borrego P, Fonseca C Abstract PURPOSE: ApneaLink is a portable device for the screening of sleep apnea, a prevalent and underdiagnosed comorbidity in heart failure patients. A prospective cross-sectional study in patients with chronic heart failure was carried out to assess the sensitivity and specificity of apnea-hypopnea index (AHI) measurements using ApneaLink against the standard polysomnography test. METHODS: Adult patients with a prior hospitalization in an acute heart failure hospital unit were recruited for the study. All participants were tested for sleep apnea using ApneaLink and polysomnography ...
Source: Sleep and Breathing - Category: Sleep Medicine Authors: Tags: Sleep Breath Source Type: research
More News: Brain | Cardiology | Heart | Heart Failure | Neurology | Neuroscience | Respiratory Medicine | Sleep Apnea | Sleep Disorders | Sleep Medicine